Therapeutic Antibodies Development for Liver Disease

Ace Therapeutics is an expert in the field of liver disease research. Based on our extensive research experience and advanced technology platform, we aim to provide the most specialized research services to developers of therapeutic antibodies targeting liver disease worldwide.

Antibodies, especially monoclonal antibodies, are characterized by high specificity, high affinity, and remarkable potency. These advantages allow them to show advantages unmatched by other types of drugs. The discovery of therapeutic antibodies has solved some of the hard-to-tackle diseases. In the field of liver disease, antibodies have also demonstrated unique superiority. We offer a comprehensive service to target antibody discovery for the treatment of liver disease.

What Can We Do?

In view of the superiority of antibodies in the field of disease treatment, and the current studies have shown that antibodies can effectively alleviate the damage of liver diseases, we provide comprehensive development services for the therapeutic effects of antibodies on different liver diseases, in order to find better liver disease therapies.

• Antibodies targeting inflammatory signaling pathways can effectively modulate the inflammatory process in the pathological process of liver disease; therefore, we will screen and identify promising inflammatory targets by gene microarray technology, protein microarray technology, and other high-throughput screening technologies, and provide antibody development and therapeutic efficacy assessment services against inflammatory targets.
• For targets that affect cellular activity, such as tyrosine kinases and other targets, we perform high-throughput screening of cell cycle targets and identify candidate targets. We then develop appropriate antibody development programs based on specific targets.
• In addition, immune response, angiogenesis, and other processes all have important regulatory roles in the pathological process of liver disease. Therefore, we will provide comprehensive antibody development and evaluation services for each of these important processes.
• We will offer different models of liver disease to fully evaluate the therapeutic effects of candidate antibodies from different perspectives.
• We have well-established antibody development platforms such as the hybridoma technology platform, phage display antibody library technology platform, and single B-cell antibody preparation platform. Based on our comprehensive antibody development platform, we aim to customize the appropriate therapeutic antibody for you.
• We will provide a comprehensive pathological examination of animal models, including but not limited to morphological examination, pathological sections, immunohistochemistry, and other assays to assess the extent of tissue damage.
• We will provide comprehensive evaluation services for the development of therapeutic antibodies against liver disease, including but not limited to different testing services such as physicochemical properties, immunogenicity, post-translational modifications, antibody aggregation, and pharmacokinetic testing.

Ace Therapeutics has extensive research experience in the field of therapeutic antibody development. With years of research experience, our scientists have integrated therapeutic antibodies and liver disease treatment and have established perfect therapeutic antibody development services for liver disease. If you would like to learn more about our services, please feel free to contact us.

Reference

1. Zhang, D., et al., The molecular mechanisms of liver fibrosis and its potential therapy in application. Int J Mol Sci, 2022. 23(20).

Our products and services are for research use only and can not be used for diagnostic or other purposes.